Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Transcriptome of Indian pediatric BCP-ALL patients

PROVIDER: PRJNA1226392 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32423924_1.fastq.gz	Fastqsanger.gz
	SRR32423924_2.fastq.gz	Fastqsanger.gz
	SRR32423925_1.fastq.gz	Fastqsanger.gz
	SRR32423925_2.fastq.gz	Fastqsanger.gz
	SRR32423926_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Whole transcriptome analysis to detect fusion genes in pediatric BCP-ALL

Project description:Whole transcriptome RNA-seq of pediatric infant (<1year of aget at diagnosis) patients affected by B-cell precursor Acute Lymphoblastic leukemia (BCP-ALL). The aim of the study is to identify fusion gene rearrangements involved in childhood leukemia, using Next Generation Sequencing (NGS)

2021-10-25 | E-MTAB-9925 | biostudies-arrayexpress

Project description:Transcriptome of Indian pediatric ALL patients

| PRJNA1426152 | ENA

Expression data from mesenchymal stromal cells derived from pediatric leukemia patients and healthy pediatric controls

Project description:B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells reside in the bone marrow microenvironment, where they are protected against chemotherapeutic agents. Mesenchymal stromal cells (MSCs) are key components of this supporting framework. The present study aimed to unravel whether MSCs derived from pediatric BCP-ALL patients (leukemic MSCs) differ from MSCs derived from healthy pediatric donors (control-MSCs). Therefore, we studied their gene expression profiles.

2020-07-13 | GSE101425 | GEO

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia

Project description:In contrast to patients with B cell precursor acute lymphoblastic leukemia (BCP-ALL), patients with acute myeloid leukemia (AML) have not yet benefited from recent advances in targeted immunotherapy. Repurposing immunotherapies that have been successfully used to target other hematological malignancies could, in case of a shared target antigen, represent a promising opportunity to expand the immunotherapeutic options for AML. Here, we evaluated the expression of CD19 in a large pediatric AML cohort, assessed the ex vivo AML killing efficacy of CD19-directed immunotherapies, and characterized the bone marrow immune microenvironment in pediatric AML, BCP-ALL, and non-leukemic controls. Out of 167 newly diagnosed de novo pediatric AML patients, 18 patients (11%) had CD19+ AML, with 61% carrying the translocation t(8;21)(q22;q22). Among CD19+ samples, we observed a continuum of CD19 expression levels on AML cells. In individuals exhibiting unimodal and high CD19 expression, the antigen was consistently present on nearly all CD34+CD38- and CD34+CD38+ subpopulations. In ex vivo AML-T cell co-cultures, blinatumomab demonstrated substantial AML killing, with an efficacy similar to BCP-ALL. In addition, CAR T cells could effectively eliminate CD19+ AML cells ex vivo. Furthermore, our immunogenomic assessment of the bone marrow immune microenvironment of newly diagnosed pediatric t(8;21) AML revealed that T- and NK cells had a less exhausted and senescent phenotype in comparison to pediatric BCP-ALL. Altogether, our study underscores the promise of CD19-directed immunotherapies for the treatment of pediatric CD19+ AML.

2024-08-08 | GSE270185 | GEO

Targeted RNA-seq of BCP-ALL pediatric patients

Project description:Targeted RNA-seq of BCP-ALL pediatric patients

| PRJEB42250 | ENA

Expression data of mesenchymal stromal cells after 40 hours of co-culture with primary B-cell precursor acute lymphoblastic leukemia cells

2020-07-13 | GSE101454 | GEO

Targeted RNA-seq of BCP-ALL pediatric patients

Project description:Targeted RNA-seq of pediatric infant (<1year of age at diagnosis) patients affected by B-cell precursor Acute Lymphoblastic leukemia (BCP-ALL). The aim of the study is to identify fusion gene rearrangements involved in childhood leukemia, using a custom targeted panel for RNA analysis by NGS.

2021-10-25 | E-MTAB-9971 | biostudies-arrayexpress

Acute lymphoblastic leukemia in children produces endogenous T-cells targeting tumor associated antigens and neoantigens in peripheral blood

Project description:In this study we investigated the presence of endogenous T-cells recognizing private tumor-associated antigens and predicted neoantigens. To this end, HLA-I and HLA-II restricted tumor associated antigens (TAAs) and neoantigens were respectively identified and predicted. Of interest, circulating T-cells targeting both Mass spectrometry (MS)-identified TAAs and predicted neoantigens were identified in virtually all pediatric BCP-ALL patients, extending up to two years on remission.

2025-07-14 | PXD061914 | Pride

Early Relapse in ALL is identified by Time To Leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways

Project description:Gene expression analysis identified a specific signature of differentially expressed genes discriminating TTLshort and TTLlong phenotypes. Gene expression signatures of xenografted leukemia samples with different TTL phenotypes were analyzed on cohorts of pediatric BCP-ALL patients.

2011-02-10 | GSE13576 | GEO

Early Relapse in ALL is identified by Time To Leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways

2011-02-10 | E-GEOD-13576 | biostudies-arrayexpress